ReviewMemo2016
PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.
Review in Memo, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.Cancer immunology, immunotherapy : CII · 2024Article
- Current Understanding of PCSK9 and Its Relevance to Cancer Prognosis and Immune Therapy: A Review.Iranian journal of pathology · 2024Review
- Apolipoprotein E is a Potential Biomarker for Predicting Cancer Prognosis and is Correlated with Immune Infiltration.OncoTargets and therapy · 2024Article
- Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.Oncology letters · 2023Article
- Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis.Experimental and therapeutic medicine · 2023Article
- Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.Frontiers in medicine · 2023Article
- Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers.World journal of gastrointestinal oncology · 2022Review
- B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.Cancer medicine · 2022Article
- PD-L1 immunostaining: what pathologists need to know.Diagnostic pathology · 2021Review
- Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors.Cellular & molecular immunology · 2021Article
- Review
- Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer.Translational oncology · 2021Article
- A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer.Cancer management and research · 2021Article
- RAGE Signaling in Melanoma Tumors.International journal of molecular sciences · 2020Review
- Targeting the immune milieu in gastrointestinal cancers.Journal of gastroenterology · 2020Review
- Article
- MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers.Gastroenterology research and practice · 2019Article
- Clinical genetic features and related survival implications in patients with surgically resected large-cell lung cancer.Cancer management and research · 2019Article
- Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1). Checkpoint inhibitors (ICI) provide encouraging therapeutic results in non-small cell lung cancers (NSCLC) and may soon be used in 2nd or 1st line therapy. Currently PD-L1 immunohistochemistry (IHC) expression assessed on tumour cells is used as a predictive biomarker, since better patient outcomes are often, but not always associated with increased tumour cell PD-L1 IHC expression. However pre-analytical variables, different anti-PD-L1 clones used on different staining platforms, different specimens types, as well as intra- and interobserver variability influence the results. We will only understand PD-L1 expression on tumour cells if we accept that PD-L1 is an inducible pathophysiological factor with variable levels of PD-L1 expression depending on the immunological status. Should we test PD-L1 during initial diagnostic work up before, or at the point when immune checkpoint therapy is considered? Taking all arguments into account the value of PD-L1 as a predictive biomarker is questionable. Other predictive biomarkers such as high mutation burden, mRNA expression, neo-antigens and the diversity of tumour antigen-specific T cells should be evaluated in the future. Here we review results presented in 30 journal articles and three reviews covering this topic in the last 3 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.